don't you think it's a crucial question - will Vascepa alone cause a significant decrease in CVD?
Of course I do - for my own personal health if nothing else - the scientific curiosity in me also wants to know the answer to that question. The NIH funds tons of research on cheap generic meds as you mention - but unless they can either get AMRN to donate years of V to a few thousand patients, or Teva once they start making it, the trial we want isn't going to happen, because V is just too expensive at current prices and production processes. As a CVD drug it's cheap, but in raw dollars it's not - R-IT cost AMRN something like $400M - that's a HUGE amount compared to available NIH research funding.
According to this table, "cardiovascular" was the #1 killer in the US in 2015, 1,464,485 deaths, and received $2.3B in 2018 funding, while "heart disease" killed 1,202,319 and got $1.5B in funding - repeating R-IT with V only would take a large % of annual funding for one of those two categories, even with $400M spread out during 4-5 yrs:
News 
Market Data 
Discover 
AI
